Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Phase 2 Completed 244 enrolled Vir Biotechnology, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy

Timeline

Start: 2021-07-11
Primary completion: 2026-03-16
Completion: 2026-03-16

Publications

Noack J, Anglero-Rodriguez Y, Gall J, Zhou J, LeBlanc S, Liebow A, Bakardjiev A, Hebner CM, Purcell LA, Jadhav V, Corti D, Lempp FA. Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical in vivo models. Antimicrob Agents Chemother. 2026 Mar 4;70(3):e0112725. doi: 10.1128/aac.01127-25. Epub 2026 Jan 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Peginterferon alfa-2a	Protein / enzyme biologic	—	Subcutaneous
Subject	Tobevibart	Monoclonal antibody	—	Subcutaneous
Subject	VIR-2218	Small interfering RNA (siRNA)	—	Subcutaneous

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Summary

Timeline

Publications

Drugs

Indications